ES2423029T3 - Compuestos de arilsulfonamida - Google Patents

Compuestos de arilsulfonamida Download PDF

Info

Publication number
ES2423029T3
ES2423029T3 ES07864478T ES07864478T ES2423029T3 ES 2423029 T3 ES2423029 T3 ES 2423029T3 ES 07864478 T ES07864478 T ES 07864478T ES 07864478 T ES07864478 T ES 07864478T ES 2423029 T3 ES2423029 T3 ES 2423029T3
Authority
ES
Spain
Prior art keywords
compound
alkyl
rheteroaryl
raryl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07864478T
Other languages
English (en)
Spanish (es)
Inventor
Jonathan Bayldon Baell
Guillaume Laurent Lessene
Brad Edmund Sleebs
Wayne J. Fairbrother
John A. Flygare
Michael F.T. Koehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Genentech Inc
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research, Genentech Inc filed Critical Walter and Eliza Hall Institute of Medical Research
Application granted granted Critical
Publication of ES2423029T3 publication Critical patent/ES2423029T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES07864478T 2006-11-15 2007-11-15 Compuestos de arilsulfonamida Active ES2423029T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85931506P 2006-11-15 2006-11-15
US859315P 2006-11-15
PCT/US2007/084873 WO2008061208A2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Publications (1)

Publication Number Publication Date
ES2423029T3 true ES2423029T3 (es) 2013-09-17

Family

ID=39276199

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07864478T Active ES2423029T3 (es) 2006-11-15 2007-11-15 Compuestos de arilsulfonamida

Country Status (9)

Country Link
US (1) US8168645B2 (enExample)
EP (1) EP2094672B1 (enExample)
JP (1) JP5366817B2 (enExample)
CN (1) CN101535280B (enExample)
AU (1) AU2007319209B2 (enExample)
CA (1) CA2666837C (enExample)
ES (1) ES2423029T3 (enExample)
NZ (1) NZ577442A (enExample)
WO (1) WO2008061208A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
US20110053873A1 (en) 2008-02-01 2011-03-03 Takeda Pharmaceutical Company Limited Hsp90 inhibitors
AU2009249106A1 (en) * 2008-05-21 2009-11-26 Genentech, Inc. Arylsulfonamide compounds, compositions and methods of use
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
AU2010294292B2 (en) * 2009-09-10 2013-07-18 Novartis Ag Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
CA2859385A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
JP2015503515A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物および組成物
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
IL311537A (en) 2014-01-28 2024-05-01 Mayo Found Medical Education & Res Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
SG11202005785XA (en) 2018-01-10 2020-07-29 Recurium Ip Holdings Llc Benzamide compounds
CN108276395B (zh) * 2018-02-09 2021-02-26 合肥华方医药科技有限公司 一种多沙唑嗪杂质的制备方法
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ATE372330T1 (de) 2002-03-21 2007-09-15 Abbott Lab N-sulfonylurea-apoptosis-förderer
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
KR101132905B1 (ko) 2003-11-20 2012-04-03 미츠비시 가스 가가쿠 가부시키가이샤 액상 시클로헥산트리카르복실산 무수물
JP5284641B2 (ja) * 2004-05-26 2013-09-11 アボット・ラボラトリーズ Ｎ−スルホニルカルボキシイミドアミドアポトーシス促進剤
CA2577752A1 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
US8101619B2 (en) 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
TWI337608B (en) 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters

Also Published As

Publication number Publication date
JP2010510237A (ja) 2010-04-02
EP2094672B1 (en) 2013-05-29
WO2008061208A3 (en) 2008-07-03
AU2007319209B2 (en) 2012-04-19
EP2094672A2 (en) 2009-09-02
US20100056517A1 (en) 2010-03-04
CN101535280B (zh) 2012-06-27
CA2666837C (en) 2015-01-13
WO2008061208A2 (en) 2008-05-22
CN101535280A (zh) 2009-09-16
AU2007319209A1 (en) 2008-05-22
CA2666837A1 (en) 2008-05-22
NZ577442A (en) 2012-02-24
JP5366817B2 (ja) 2013-12-11
HK1134283A1 (en) 2010-04-23
US8168645B2 (en) 2012-05-01

Similar Documents

Publication Publication Date Title
ES2423029T3 (es) Compuestos de arilsulfonamida
ES2967983T3 (es) Compuestos
ES2729424T3 (es) Inhibidores de Rho cinasa
ES2927182T3 (es) Agentes inductores de la apoptosis
ES2855135T3 (es) Amidas heterocíclicas como inhibidores de quinasa
ES2466818T3 (es) Moduladores c-Met y métodos de uso
ES2360936T3 (es) Indoles sustituidos.
CN108834412B (zh) 嘧啶及其变体、及其用途
ES2802251T3 (es) Compuestos heterocíclicos y métodos para su uso
ES2284007T3 (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
ES2816641T3 (es) Derivados de piperidina en calidad de inhibidores de HDAC1/2
ES2399427T3 (es) Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa
ES2379874T3 (es) Compuestos de (2-carboxamido)(3-amino)tiofeno
CA2871453A1 (en) Quinazolinedione derivative
CN113924288B (zh) 一种含喹啉基化合物、药物组合物以及其用途
CN106478606A (zh) N‑取代吲哚类衍生物及其应用
ES2362949T3 (es) Carboxamidas substituidas como antagonistas del receptor metabotrópico de grupo i.
ES2905985T3 (es) Compuesto de oxazino-quinazolina y de tipo oxazino-quinazolina, método de preparación y usos de los mismos
ES2936482T3 (es) Agentes antiinfecciosos
US20210070742A1 (en) Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
CN103965182A (zh) 制备含1,3,4-噁二唑的吡唑类化合物用于治疗肿瘤的药物
ES2301984T3 (es) Dihidroquinazolinas sustituidas con heterociclilo y su uso como agente antivirico.
ES2893001T3 (es) Nuevos derivados de dihidropiranopirimidinona y su uso
ES2328929T3 (es) Dihidroquinazolinas 2-sustituidas.
ES2876285T3 (es) Derivados de acetamida de 2-(1,2,4-triazol-3-ilsulfanil)-N-1,3,4-tiadiazol-2-ilo que son útiles para el tratamiento de la diabetes